NURS 7430 Advanced Pharm Exam Questions With Correct Answers

NURS 7430 Advanced Pharm Exam
Questions With Correct Answers
If |a |patient |has |a |true |penicillin |allergy |(anaphylaxis) |which |of |the |following |would |be |
contraindicated?

a. |Zosyn

b. |Unasyn

c. |Augmentin

d. |Penicillin |V

e. |All |of |the |above |- |CORRECT |ANSWER✔✔-e. |All |of |the |above



Which |of |the |following |antibiotics |should |not |be |given |to |pregnant |women?

a. |sulfonamide/ |trimethoprim |(Bactrim)

b. |Erythromycin

c. |Cephalexin |(Keflex)

d. |Amoxicillin |with |clavulanic |acid |(Augmentin) |- |CORRECT |ANSWER✔✔-a. |sulfonamide/ |
trimethoprim |(Bactrim)



Erythromycin, |PCN |and |cephalosporins |are |not |considered |tetratrogenic |but |sulfamethozoles |
may |cause |congenital |malformations |such |as |neural |tube |defects.



Which |of |the |following |concepts |would |not |be |involved |in |active |transport |of |drugs?

a. |consumption |of |energy

b. |specific |carrier

c. |could |be |saturable

d. |movement |due |to |the |concentration |gradient |- |CORRECT |ANSWER✔✔-d. |movement |due |to |
the |concentration |gradient

,Passive |diffusion |is |driven |by |concentration |gradient. |Active |CARRIER |transport |requires |energy
|and |a |specific |carrier |which |can |be |saturated |if |too |much |medication |is |available




What |is |the |primary |mechanism |of |action |of |Fluoroquinolones?

a. |Inhibiting |RNA-dependant |protein |synthesis

b. |Affecting |folic |acid |synthesis |in |bacteria

c. |Inhibiting |bacterial |cell |wall |synthesis

d. |Inhibiting |DNA |gyrase |and |topoisomerase

e. |Binding |to |bacteria |ribosomes |- |CORRECT |ANSWER✔✔-d. |Inhibiting |DNA |gyrase |and |
topoisomerase



How |do |Azole |antifungals |primarily |work?

a. |Inhibiting |glucan |synthesis

b. |Binding |to |sterols |in |the |fungal |cell |wall

c. |Inhibiting |fungal |enzymes

d. |Inhibiting |DNA |gyrase |and |topoisomerase |- |CORRECT |ANSWER✔✔-c. |Inhibiting |fungal |
enzymes



What |is |the |mechanism |of |action |of |Cephalosporins?

a. |Inhibiting |bacterial |cell |wall |synthesis

b. |Inhibiting |DNA |gyrase |and |topoisomerase

c. |Affecting |folic |acid |synthesis |in |bacteria

d. |Binding |to |bacteria |ribosomes

e. |Inhibiting |RNA-dependant |protein |synthesis |- |CORRECT |ANSWER✔✔-a. |Inhibiting |bacterial |
cell |wall |synthesis

,Which |of |the |following |is |an |effect |of |antiviral |drugs? |Select |all |that |apply.

a. |Antivirals |block |viral |movement |from |the |host |cell |into |the |blood.

b. |Antivirals |interfere |with |virus |synthesis |or |maturation.

c. |Antivirals |kill |extracellular |viruses.

d. |Antivirals |block |cellular |receptors |so |viruses |can |not |bind |with |the |host |cell. |- |CORRECT |
ANSWER✔✔-a, |b, |d



Antivirals |work |by |blocking |the |viruses |ability |to |replicate |in |some |fashion. |Once |a |new |virus |
has |been |created |and |released |into |circulation, |antivirals |aren't |able |to |destroy |them.



If |a |person |is |given |2 |medications |and |Medication |A |induces |the |CYP |- |450 |enzyme |group |that
|is |responsible |for |metabolizing |Medication |B |- |How |would |you |expect |that |to |impact |the |drug


|levels |for |Medication |B?



a. |decrease |level |of |Medication |B

b. |increase |level |of |Medication |B

c. |no |impact |on |level |of |Medication |B |- |CORRECT |ANSWER✔✔-a. |decrease |level |of |Medication
|B




Which |of |the |following |is |a |saturable |transport |system?

a. |Water-soluble |diffusion |-- |water |based

b. |Passive |diffusion |-- |concentration |dependent

c. |Lipid-soluble |diffusion |-- |fat |based

d. |Facilitated |diffusion |-- |carrier |mediated |- |CORRECT |ANSWER✔✔-d. |Facilitated |diffusion |-- |
carrier |mediated



Depends |on |a |carrier |protein |and |like |active |transport |(that |requires |energy) |can |be |saturated |
and |may |be |inhibited |by |compounds |that |compete |for |the |carrier.

, A |patient |presents |with |an |overdose |of |alkaline |Codeine. |What |drug |can |be |given |to |trap |the |
Codeine |to |prevent |further |metabolism; |and, |how |will |the |pH |of |the |urine |be |changed?

a. |NaHCO3; |Decrease

b. |NH4Cl; |Increase

c. |NH4Cl; |Decrease

d. |NaHCO3; |Increase |- |CORRECT |ANSWER✔✔-c. |NH4Cl; |Decrease



Remember |- |like |ionization |promotes |absorption |and |different |ionization |promotes |excretion |- |
so |making |the |urine |MORE |acidic |(decreasing |the |pH) |will |INCREASE |the |excretion |of |an |
alkaline |drug.



What |are |the |characteristics |of |drugs |that |are |excreted |through |passive |diffusion |out |of |the |
renal |tubules?

a. |Non-Polar |and |lipophylic

b. |Non-Polar |and |hydrophobic

c. |Polar |and |hydrophyllic

d. |Polar |and |lipophylic |- |CORRECT |ANSWER✔✔-c. |Polar |and |hydrophyllic



Water |is |polar |thus |drugs |that |are |polar |and |hydrophyllic |(ie |water |soluble) |are |more |easily |
excreted



A |drug |if |unchanged |will |diffuse |out |of |the |nephric |lumen, |back |into |systemic |circulation |do |to
|differences |in |the |concentration |gradient.




What |is |a |Polymorphism |of |B-adrenergic |receptor |is |an |example |of?

a. |Pharmacokinetic |polymorphism

b. |Pharmacodynamic |polymorphism

c. |Pharmacogenetics